Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ia/Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of IBI397 or Combination Therapies in Patients With Advanced Malignancies

Next Previous
Search
Trial Profile

A Phase Ia/Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of IBI397 or Combination Therapies in Patients With Advanced Malignancies

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 08 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AL 008 (Primary) ; Rituximab (Primary) ; Sintilimab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Innovent Biologics

    • Most Recent Events

    • 31 Aug 2023 Planned End Date changed from 31 Dec 2023 to 24 Aug 2023.
    • 31 Aug 2023 Planned primary completion date changed from 30 Jun 2023 to 24 Aug 2023.
    • 31 Aug 2023 Planned initiation date changed from 7 Feb 2022 to 14 Apr 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top